Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial

Nicotine and Tobacco Research

Volumn 11, Issue 4, 2009, Pages 404-407

  Munafò, Marcus R ^a   Johnstone, Elaine C ^b   Murphy, Michael F G ^b   Aveyard, Paul ^c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; NICOTINE PATCH; THYMIDINE;

ADULT; AGED; ALLELE; ARTICLE; BEHAVIOR THERAPY; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG RESPONSE; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NICOTINE REPLACEMENT THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT DURATION;

ADULT; AGED; ALLELES; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINE; PLACEBOS; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D2; SEX FACTORS; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER; YOUNG ADULT;

EID: 65549147309     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntp007     Document Type: Article

References (30)

1. Aveyard, P., Brown, K., Saunders, C., Alexander, A., Johnstone, E. C., Munafò, M. R., et al. (2007). Weekly versus basic smoking cessation support in primary care: A randomised controlled trial. Thorax, 62 898-903.
2. Dahl, J. P., Jepson, C., Levenson, R., Wileyto, E. P., Patterson, F., Berrettini, W. H., et al. (2006). Interaction between variation in the D2 dopamine receptor (DRD2) and the neuronal calcium sensor-1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence. Pharmacogenomics Journal, 6, 194-199.
3. David, S. P., Munafò, M. R., Murphy, M. F., Proctor, M., Walton, R. T., & Johnstone, E. C. (2007). Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: Follow-up of a randomised clinical trial of transdermal nicotine patch. Pharmacogenomics Journal, 8, 122-128.
4. David, S. P., Munafò, M. R., Murphy, M. F., Walton, R. T., & Johnstone, E. C. (2007). The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: Follow-up of a randomized controlled trial. Nicotine & Tobacco Research, 9, 225-231.
5. Gelernter, J., Yu, Y., Weiss, R., Brady, K., Panhuysen, C., Yang, B. Z., et al. (2006). Haplotype spanning TTC12 and ANKK1, flanked by the DRD2 and NCAM1 loci, is strongly associated to nicotine dependence in two distinct American populations. Human Molecular Genetics, 15, 3498-3507.
6. Gwinn, M., Guessous, I., & Khoury, M. (2008). "Intention to analyze" in pharmacogenomics studies. Cancer Epidemiology Biomarkers and Prevention, 17, 740.
7. Hughes, J. R. (2003). Motivating and helping smokers to stop smoking. Journal of General Internal Medicine, 18, 1053-1057.
8. Ioannidis, J. P., Ntzani, E. E., Trikalinos, T. A., & Contopoulos-Ioannidis, D. G. (2001). Replication validity of genetic association studies. Nature Genetics, 29, 306-309.
9. Johnstone, E. C., Elliot, K. M., David, S. P., Murphy, M. F., Walton, R. T., & Munafò, M. R. (2007). Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiology, Biomarkers, and Prevention, 16 1065-1069.
10. Johnstone, E. C., Yudkin, P. L., Hey, K., Roberts, S. J., Welch, S. J., Murphy, M. F., et al. (2004). Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics, 14, 83-90.
11. Jonsson, E. G., Nothen, M. M., Grunhage, F., Farde, L., Nakashima, Y., Propping, P., et al. (1999). Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Molecular Psychiatry, 4, 290-296.
12. Lerman, C., Jepson, C., Wileyto, E. P., Epstein, L. H., Rukstalis, M., Patterson, F., et al. (2006). Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: Results of two randomized clinical trials. Neuropsychopharmacology, 31, 231-242.
13. Lerman, C., Tyndale, R., Patterson, F., Wileyto, E. P., Shields, P. G., Pinto, A., et al. (2006). Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clinical Pharmacology and Therapeutics, 79, 600-608.
14. Lerman, C., Wileyto, E. P., Patterson, F., Rukstalis, M., Audrain-McGovern, J., Restine, S., et al. (2004). The functional muopioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics Journal, 4, 184-192.
15. Malaiyandi, V., Lerman, C., Benowitz, N. L., Jepson, C., Patterson, F., & Tyndale, R. F. (2006). Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Molecular Psychiatry, 11, 400-409.
16. Munafò, M. R., Clark, T., Johnstone, E. C., Murphy, M., & Walton, R. T. (2004). The genetic basis for smoking behavior: A systematic review and meta-analysis. Nicotine and Tobacco Research, 6, 583-597.
17. Munafò, M. R., Johnstone, E. C., Guo, B., Murphy, M. F., & Aveyard, P. (2008). Association of COMT Val108/158Met genotype with smoking cessation. Pharmacogenetics and Genomics, 18, 121-128.
18. Munafò, M. R., Johnstone, E. C., Murphy, M. F., & Aveyard, P. (2008). "Intention to analyze" in pharmacogenomics studies. Cancer Epidemiology, Biomarkers, and Prevention, 17, 740-741.
19. Munafò, M. R., Johnstone, E. C., Wileyto, E. P., Shields, P. G., Elliot, K. M., & Lerman, C. (2006). Lack of association of 5-HTTLPR genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiology, Biomarkers, and Prevention, 15 398-400.
20. Munafò, M. R., Lerman, C., Niaura, R., Shields, A. E., & Swan, G. E. (2005). Smoking cessation treatment: Pharmacogenetic assessment. Current Opinion in Molecular Therapeutics, 7, 202-208.
21. Munafò, M. R., Shields, A. E., Berrettini, W. H., Patterson, F., & Lerman, C. (2005). Pharmacogenetics and nicotine addiction treatment. Pharmacogenomics, 6, 211-223.
22. Munafò, M. R., Stothart, G., & Flint, J. (2009). Bias in genetic association studies and impact factor. Molecular Psychiatry, 14, 119-120.
23. Munafò, M. R., Timpson, N. J., David, S. P., Ebrahim, S., & Lawlor, D. A. (2009). Association of the DRD2 gene Taq1A polymorphism and smoking behaviour: A meta-analysis and new data. Nicotine & Tobacco Research, 11, 64-76.
24. Neville, M. J., Johnstone, E. C., & Walton, R. T. (2004). Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Human Mutation, 23, 540-545.
25. Patsopoulos, N. A., Tatsioni, A., & Ioannidis, J. P. (2007). Claims of sex differences: An empirical assessment in genetic associations. The Journal of the American Medical Association, 298, 880-893.
26. Society for Research on Nicotine and Tobacco. (2002). Biochemical verification of tobacco use and cessation. Nicotine & Tobacco Research, 4, 149-159.
27. Welton, N. J., Johnstone, E. C., David, S. P., & Munafò, M. R. (2008). A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation. Nicotine & Tobacco Research, 10, 231-240.
28. West, R. (2006). Smoking and smoking cessation in England: 2006, Retrieved July 27, 2007, http://www.smokinginengland.info/Ref/paper4.pdf
29. West, R., Hajek, P., Stead, L., & Stapleton, J. (2005). Outcome criteria in smoking cessation trials: Proposal for a common standard. Addiction, 100, 299-303.
30. Yudkin, P., Munafò, M. R., Hey, K., Roberts, S., Welch, S., Johnstone, E. C., et al. (2004). Effectiveness of nicotine patches in relation to genotype in women versus men: Randomised controlled trial. British Medical Journal, 328, 989-990.